| Year |
Citation |
Score |
| 2024 |
Van Berckelaer C, Van Laere S, Lee S, Morse MA, Geradts J, Dirix L, Kockx M, Bertucci F, Van Dam P, Devi GR. XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant. Translational Oncology. 43: 101907. PMID 38412664 DOI: 10.1016/j.tranon.2024.101907 |
0.41 |
|
| 2023 |
Gearhart-Serna LM, Mills BA, Hsu H, Fayanju OM, Hoffman K, Devi GR. Cumulative environmental quality is associated with breast cancer incidence differentially by summary stage and urbanicity. Scientific Reports. 13: 20301. PMID 37985794 DOI: 10.1038/s41598-023-45693-0 |
0.311 |
|
| 2023 |
Rickard AG, Sannareddy DS, Bennion A, Patel P, Sauer SJ, Rouse DC, Bouchal S, Liu H, Dewhirst MW, Palmer GM, Devi GR. A Novel Preclinical Murine Model to Monitor Inflammatory Breast Cancer Tumor Growth and Lymphovascular Invasion. Cancers. 15. PMID 37190189 DOI: 10.3390/cancers15082261 |
0.384 |
|
| 2022 |
Al Abo M, Gearhart-Serna L, Van Laere S, Freedman JA, Patierno SR, Hwang ES, Krishnamurthy S, Williams KP, Devi GR. Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences. Npj Breast Cancer. 8: 73. PMID 35697736 DOI: 10.1038/s41523-022-00431-z |
0.417 |
|
| 2021 |
Schirmer AU, Driver LM, Zhao MT, Wells CI, Pickett JE, O'Bryne SN, Eduful BJ, Yang X, Howard L, You S, Devi GR, DiGiovanni J, Freedland SJ, Chi JT, Drewry DH, et al. Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 34450249 DOI: 10.1016/j.ymthe.2021.08.029 |
0.333 |
|
| 2021 |
Devi GR, Finetti P, Morse MA, Lee S, de Nonneville A, Van Laere S, Troy J, Geradts J, McCall S, Bertucci F. Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. Cancers. 13. PMID 34199946 DOI: 10.3390/cancers13112807 |
0.397 |
|
| 2021 |
Sauer S, Beinart D, Finn SMB, Kumar SL, Cheng Q, Hwang SE, Parker W, Devi GR. -based helminth therapy in C3(1)-TAg mice does not alter breast tumor onset or progression. Evolution, Medicine, and Public Health. 9: 131-138. PMID 33738103 DOI: 10.1093/emph/eoab007 |
0.358 |
|
| 2020 |
Xie X, Lee J, Liu H, Pearson T, Lu AY, Tripathy D, Devi GR, Bartholomeusz C, Ueno NT. Birinapant Enhances Gemcitabine's Anti-tumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. Molecular Cancer Therapeutics. PMID 33323457 DOI: 10.1158/1535-7163.MCT-19-1160 |
0.492 |
|
| 2020 |
Gearhart-Serna LM, Davis JB, Jolly MK, Jayasundara N, Sauer SJ, Di Giulio RT, Devi GR. A polycyclic aromatic hydrocarbon-enriched environmental chemical mixture enhances AhR, antiapoptotic signaling and a proliferative phenotype in breast cancer cells. Carcinogenesis. PMID 32747956 DOI: 10.1093/Carcin/Bgaa047 |
0.534 |
|
| 2020 |
Gearhart-Serna LM, Hoffman K, Devi GR. Environmental Quality and Invasive Breast Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 32238404 DOI: 10.1158/1055-9965.Epi-19-1497 |
0.402 |
|
| 2020 |
Rypens C, Marsan M, Van Berckelaer C, Billiet C, Melis K, Lopez SP, van Dam P, Devi GR, Finetti P, Ueno NT, Bertucci F, Dirix P, Neven P, Vermeulen P, Dirix L, et al. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment. PMID 32043194 DOI: 10.1007/S10549-020-05571-Z |
0.522 |
|
| 2020 |
Fayanju OM, Ren Y, Greenup RA, Plichta JK, Rosenberger LH, Force J, Suneja G, Devi GR, King TA, Nakhlis F, Hyslop T, Hwang ES. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Research and Treatment. PMID 31960171 DOI: 10.1007/S10549-020-05529-1 |
0.374 |
|
| 2020 |
Gearhart-Serna LM, Hoffman K, Devi GR. Abstract B122: Spatial analysis of ductal carcinoma in situ, locoregional, and distant metastatic breast cancer in North Carolina: Evidence for rural-urban disparities Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B122 |
0.385 |
|
| 2020 |
Devi GR, Abo MA, Gearhart-Serna L, Geradts J, McCall SJ, Krishnamurthy S. Abstract B035: Identification of a tumor cell adaptive stress response signaling pathway, which drives aggressive breast cancer phenotype and therapeutic resistance, in African American patients with locally advanced breast cancer subtypes Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B035 |
0.51 |
|
| 2020 |
Gerahart-Serna L, Lane W, Fish L, Tran AN, Devi GR, Hough H, Ingraham KL. Abstract B034: Improving patient-centered care for inflammatory breast cancer: Strategies for addressing barriers faced by patients, researchers, and providers Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B034 |
0.372 |
|
| 2020 |
Williams KP, Barrett NJ, Oldham CE, Hough H, Woodard A, Freedman J, Devi GR, Patierno SR. Abstract IA18: North Carolina Central University and Duke Cancer Institute's collaborative cancer research and education program: Connecting cancer disparities translational research, clinical trials operations, and community engagement Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-Ia18 |
0.34 |
|
| 2020 |
Dixon MS, Chdid L, Lamson DR, Tarpley MT, Oladapo HO, Fleming JM, Freedman JA, Devi GR, Williams KP. Abstract C100: Identification and functional characterization of a novel GLI1 splice variant in breast cancer Cancer Epidemiology, Biomarkers & Prevention. 29. DOI: 10.1158/1538-7755.Disp18-C100 |
0.489 |
|
| 2020 |
Dixion M, Ingraham KL, Robinson SA, Fleming JM, Devi GR, Hough H, Kharabsheh H, Austin DM, Tate TA, Woodard A, Alexander J, Packenham JP, Barrett NJ, Williams KP. Abstract A023: Results from a town hall meeting: Inflammatory breast cancer listening session led by KOMEN scholars Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp18-A023 |
0.406 |
|
| 2020 |
Rickard A, Patel P, Sauer SJ, Dewhirst MW, Palmer GM, Devi GR. Abstract P1-03-03: Multichannel serial imaging of transgenic, preclinical murine models provides the first quantitative analysis of the unusual growth kinetics and lymph-vascular invasion of patient-derived inflammatory breast cancer cells and tumor emboli Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-03-03 |
0.452 |
|
| 2019 |
Devi GR, Hough H, Barrett N, Cristofanilli M, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, et al. Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer. 10: 3344-3351. PMID 31293637 DOI: 10.7150/Jca.31176 |
0.417 |
|
| 2019 |
Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, Levine H, Onuchic JN, Jolly MK. Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America. 116: 148-157. PMID 30587589 DOI: 10.1073/Pnas.1815345116 |
0.416 |
|
| 2019 |
Devi G, Finetti P, Geradts J, McCall S, Morse M, Van Laere S, Bertucci F. Expression of x-linked inhibitor of apoptosis protein (XIAP) and its association with clinicopathological parameters in invasive breast cancers Annals of Oncology. 30: v92-v93. DOI: 10.1093/Annonc/Mdz240.098 |
0.461 |
|
| 2019 |
Rypens C, Berckelaer CV, Billiet C, Hauspy J, Bertucci F, Devi G, Vermeulen P, Dirix LY, Laere SJV. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz095.071 |
0.513 |
|
| 2018 |
Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen P, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere S, Devi GR. XIAP regulation by MNK links MAPK and NFκB signaling to determine an aggressive breast cancer phenotype. Cancer Research. PMID 29351901 DOI: 10.1158/0008-5472.Can-17-1667 |
0.696 |
|
| 2018 |
Oladapo H, Ji X, Shehata H, Tarpley M, Chdid L, Lamson D, Bao X, Sauer S, Devi GR, Williams KP. Abstract B47: Efficacy of GLI antagonists in triple-negative inflammatory breast cancer 2D and 3D models Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B47 |
0.521 |
|
| 2017 |
Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, et al. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10 Anniversary Conference. Journal of Cancer. 8: 3607-3614. PMID 29667990 DOI: 10.7150/Jca.21200 |
0.38 |
|
| 2017 |
Oladapo HO, Tarpley M, Sauer SJ, Addo KA, Ingram SM, Strepay D, Ehe BK, Chdid L, Trinkler M, Roques JR, Darr DB, Fleming JM, Devi GR, Williams KP. Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. Cancer Letters. PMID 28965853 DOI: 10.1016/J.Canlet.2017.09.033 |
0.53 |
|
| 2017 |
Crawford BM, Shammas RL, Fales AM, Brown DA, Hollenbeck ST, Vo-Dinh T, Devi GR. Photothermal ablation of inflammatory breast cancer tumor emboli using plasmonic gold nanostars. International Journal of Nanomedicine. 12: 6259-6272. PMID 28894365 DOI: 10.2147/Ijn.S141164 |
0.498 |
|
| 2017 |
Arora J, Sauer SJ, Tarpley M, Vermeulen P, Rypens C, Van Laere S, Williams KP, Devi GR, Dewhirst MW. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies. Oncotarget. 8: 25848-25863. PMID 28460441 DOI: 10.18632/Oncotarget.15667 |
0.504 |
|
| 2017 |
Sauer SJ, Tarpley M, Shah I, Save AV, Lyerly HK, Patierno SR, Williams KP, Devi GR. Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis. 38: 252-260. PMID 28426875 DOI: 10.1093/Carcin/Bgx003 |
0.553 |
|
| 2017 |
Shammas RL, Fales AM, Crawford BM, Wisdom AJ, Devi GR, Brown DA, Vo-Dinh T, Hollenbeck ST. Human Adipose-Derived Stem Cells Labeled with Plasmonic Gold Nanostars for Cellular Tracking and Photothermal Cancer Cell Ablation. Plastic and Reconstructive Surgery. 139: 900e-910e. PMID 28350664 DOI: 10.1097/Prs.0000000000003187 |
0.396 |
|
| 2017 |
Oladapo H, Sauer S, Tarpley M, Devi G, Williams KP. Abstract B49: Profiling of GLI antagonists in phenotypic models for effects on inflammatory breast cancer cell growth Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-B49 |
0.55 |
|
| 2017 |
Devi GR, Hwang ES, Stewart J, Morse MA, Laere SV. Abstract B44: Immune pathway dysregulations in inflammatory breast cancer health disparity Cancer Epidemiology, Biomarkers & Prevention. 26. DOI: 10.1158/1538-7755.Disp16-B44 |
0.524 |
|
| 2017 |
Shammas R, Fales A, Crawford B, Hollenbeck S, Vo-Dinh T, Devi G. Abstract P3-16-02: Nanotheranostics using plasmonic gold nanostars to target inflammatory breast cancer cells and tumor emboli Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-16-02 |
0.501 |
|
| 2017 |
Sauer S, Evans M, Morse M, Devi G. Abstract P2-04-21: Suppression of immune response by X-linked inhibitor of apoptosis protein-nuclear factor kappa-light-chain-enhancer of activated B cells tumor cell signaling Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P2-04-21 |
0.616 |
|
| 2016 |
Devi GR, Nath S. Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 1428: 231-43. PMID 27236803 DOI: 10.1007/978-1-4939-3625-0_15 |
0.395 |
|
| 2016 |
Nath S, Devi GR. Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. Pharmacology & Therapeutics. PMID 27063403 DOI: 10.1016/J.Pharmthera.2016.03.013 |
0.42 |
|
| 2016 |
Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death & Disease. 7: e2073. PMID 26821068 DOI: 10.1038/Cddis.2015.412 |
0.683 |
|
| 2016 |
Evans MK, Geradts J, Edwards C, Price A, Arora AJ, Aldrich AJ, Ramirez A, Robinson TJ, Vermeulen PB, Laere Sv, Devi GR. Abstract LB-015: XIAP induction by the MAPK-eIF4G1 pathway drives NFκB activation in inflammatory breast cancer growth and therapeutic resistance Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-015 |
0.713 |
|
| 2015 |
Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, Devi GR, Palmer G, Jones LW, Dewhirst MW. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. Journal of the National Cancer Institute. 107. PMID 25780062 DOI: 10.1093/Jnci/Djv040 |
0.362 |
|
| 2015 |
Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Molecular Oncology. 9: 1155-68. PMID 25769405 DOI: 10.1016/J.Molonc.2015.02.007 |
0.674 |
|
| 2015 |
Evans MK, Sauer SJ, Aldrich AJ, Geradts J, Vermeulen P, Dirix L, Laere SV, Devi GR. Abstract P6-14-05: A novel link between anti-apoptotic signaling, NFκB, and SMAD7 in IBC pathobiology Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-14-05 |
0.714 |
|
| 2015 |
Oladapo H, Fleming JM, Addo K, Tarpley M, Ehe B, Ingram S, Sauer S, Devi G, Williams KP. Abstract 680: Identification of GLI1 antagonists for breast cancer therapy Cancer Research. 75: 680-680. DOI: 10.1158/1538-7445.Am2015-680 |
0.43 |
|
| 2015 |
Price A, Edwards CM, Evans MK, Devi G. Abstract 1007: Elucidating a role for the translation initiation factor, eIF4G1, in resistance to therapy in inflammatory breast cancer (IBC) Cancer Research. 75: 1007-1007. DOI: 10.1158/1538-7445.Am2015-1007 |
0.707 |
|
| 2014 |
Evans MK, Tovmasyan A, Batinic-Haberle I, Devi GR. Mn porphyrin in combination with ascorbate acts as a pro-oxidant and mediates caspase-independent cancer cell death. Free Radical Biology & Medicine. 68: 302-14. PMID 24334253 DOI: 10.1016/J.Freeradbiomed.2013.11.031 |
0.68 |
|
| 2014 |
Oladapo H, Ingram S, Stefanowicz A, Devi G, Williams K. Abstract C42: Quantitative high-throughput efficacy profiling of hedgehog/GLI pathway antagonists in inflammatory breast cancer Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-C42 |
0.515 |
|
| 2014 |
Devi G, Allensworth J, Evans M, Ueno N, McDonnell D, Bertucci F, Van Laere S. 80 Determination of an oxidative stress gene signature in inflammatory breast cancer patient tumors and development of a novel redox modulatory strategy in overcoming chemotherapy resistance and mediating anti-tumor efficacy European Journal of Cancer. 50: 31. DOI: 10.1016/S0959-8049(14)70206-0 |
0.663 |
|
| 2014 |
Devi GR, Allensworth JL, Evans MK, Sauer SJ. The Role of Oxidative Stress in Breast Cancer Cancer: Oxidative Stress and Dietary Antioxidants. 3-14. DOI: 10.1016/B978-0-12-405205-5.00001-5 |
0.594 |
|
| 2013 |
Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Letters. 337: 77-89. PMID 23689139 DOI: 10.1016/J.Canlet.2013.05.017 |
0.428 |
|
| 2013 |
Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Annals of Surgery. 258: 879-86. PMID 23657083 DOI: 10.1097/Sla.0B013E318292919E |
0.359 |
|
| 2013 |
Morse MA, Chaudhry A, Gabitzsch ES, Hobeika AC, Osada T, Clay TM, Amalfitano A, Burnett BK, Devi GR, Hsu DS, Xu Y, Balcaitis S, Dua R, Nguyen S, Balint JP, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunology, Immunotherapy : Cii. 62: 1293-301. PMID 23624851 DOI: 10.1007/S00262-013-1400-3 |
0.333 |
|
| 2013 |
Nair S, Aldrich AJ, McDonnell E, Cheng Q, Aggarwal A, Patel P, Williams MM, Boczkowski D, Lyerly HK, Morse MA, Devi GR. Immunologic targeting of FOXP3 in inflammatory breast cancer cells. Plos One. 8: e53150. PMID 23341929 DOI: 10.1371/Journal.Pone.0053150 |
0.493 |
|
| 2013 |
Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Research and Treatment. 137: 359-71. PMID 23225169 DOI: 10.1007/S10549-012-2352-6 |
0.53 |
|
| 2013 |
Devi GR, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Williams KP. Abstract 951: Cross-resistance and re-sensitization to multiple drugs in an IBC model of lapatinib acquired resistance parallels redox adaptation. Cancer Research. 73: 951-951. DOI: 10.1158/1538-7445.Am2013-951 |
0.468 |
|
| 2013 |
Evans M, Tovmasyan A, Batinic-Haberle I, Devi G. Abstract 5552: Manganese porphyrins in combination with ascorbate act as pro-oxidants and mediate caspase-independent cancer cell death. Cancer Research. 73: 5552-5552. DOI: 10.1158/1538-7445.Am2013-5552 |
0.701 |
|
| 2012 |
Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, Lyerly HK, Diehl AM, Morse MA, Devi GR. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. Bmc Cancer. 12: 402. PMID 22963400 DOI: 10.1186/1471-2407-12-402 |
0.381 |
|
| 2012 |
Allensworth JL, Aird KM, Aldrich AJ, Batinic-Haberle I, Devi GR. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Molecular Cancer Therapeutics. 11: 1518-27. PMID 22508521 DOI: 10.1158/1535-7163.Mct-11-0787 |
0.738 |
|
| 2012 |
Osada T, Berglund P, Morse MA, Hubby B, Lewis W, Niedzwiecki D, Yang XY, Hobeika A, Burnett B, Devi GR, Clay TM, Smith J, Kim Lyerly H. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunology, Immunotherapy : Cii. 61: 1941-51. PMID 22488274 DOI: 10.1007/S00262-012-1248-Y |
0.304 |
|
| 2012 |
Morse MA, Hobeika A, Serra D, Aird K, McKinney M, Aldrich A, Clay T, Mourich D, Lyerly HK, Iversen PL, Devi GR. Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. Cancer Gene Therapy. 19: 30-7. PMID 21997230 DOI: 10.1038/Cgt.2011.63 |
0.659 |
|
| 2012 |
Aird KM, Allensworth JL, Batinic-Haberle I, Lyerly HK, Dewhirst MW, Devi GR. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Research and Treatment. 132: 109-19. PMID 21559822 DOI: 10.1007/S10549-011-1568-1 |
0.73 |
|
| 2012 |
Devi G, Allensworth J, Sauer S, Morse M, Lyerly H. 101 Smac Mimetic Induces Apoptosis and Synergizes with TRAIL in Inflammatory Breast Cancer Cells in an IAP-Dependent and TNF-a-Independent Mechanism European Journal of Cancer. 48: 32. DOI: 10.1016/S0959-8049(12)71899-3 |
0.504 |
|
| 2011 |
Lyerly HK, Hobeika A, Niedzwiecki D, Osada T, Marshall J, Garrett CR, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hsu SD, Bulusu A, Clary BM, Annechiarico R, ... Devi G, et al. A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2533. PMID 28022328 DOI: 10.1200/Jco.2011.29.15_Suppl.2533 |
0.373 |
|
| 2011 |
Morse M, Niedzwiecki D, Marshall J, Garrett CR, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika A, Osada T, Clary BM, Hsu SD, Devi G, Bulusu A, et al. Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3557. PMID 28020295 DOI: 10.1200/Jco.2011.29.15_Suppl.3557 |
0.372 |
|
| 2011 |
Ye X, Fels D, Tovmasyan A, Aird KM, Dedeugd C, Allensworth JL, Kos I, Park W, Spasojevic I, Devi GR, Dewhirst MW, Leong KW, Batinic-Haberle I. Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radical Research. 45: 1289-306. PMID 21859376 DOI: 10.3109/10715762.2011.616199 |
0.665 |
|
| 2011 |
Thomas ZI, Gibson W, Sexton JZ, Aird KM, Ingram SM, Aldrich A, Lyerly HK, Devi GR, Williams KP. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. British Journal of Cancer. 104: 1575-86. PMID 21505458 DOI: 10.1038/Bjc.2011.133 |
0.72 |
|
| 2011 |
Gupta S, Koru-Sengul T, Arnold SM, Devi GR, Mohiuddin M, Ahmed MM. Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells. Molecular Cancer Therapeutics. 10: 292-302. PMID 21216938 DOI: 10.1158/1535-7163.Mct-10-0630 |
0.397 |
|
| 2011 |
Clay TM, Osada T, Hartman ZC, Hobeika A, Devi G, Morse MA, Kim Lyerly H. Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines Immunologic Research. 49: 235-247. PMID 21136201 DOI: 10.1007/S12026-010-8186-6 |
0.374 |
|
| 2010 |
Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S, Niedzwiecki D, Devi GR, Burnett BK, Clay TM, Smith J, Lyerly HK. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. The Journal of Clinical Investigation. 120: 3234-41. PMID 20679728 DOI: 10.1172/Jci42672 |
0.398 |
|
| 2010 |
Aird KM, Ghanayem RB, Peplinski S, Lyerly HK, Devi GR. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Molecular Cancer Therapeutics. 9: 1432-42. PMID 20406946 DOI: 10.1158/1535-7163.Mct-10-0160 |
0.736 |
|
| 2010 |
Hartman ZC, Wei J, Osada T, Glass O, Lei G, Yang XY, Peplinski S, Kim DW, Xia W, Spector N, Marks J, Barry W, Hobeika A, Devi G, Amalfitano A, et al. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1466-77. PMID 20179231 DOI: 10.1158/1078-0432.Ccr-09-2549 |
0.357 |
|
| 2010 |
Morse MA, Wei J, Hartman Z, Xia W, Ren XR, Lei G, Barry WT, Osada T, Hobeika AC, Peplinski S, Jiang H, Devi GR, Chen W, Spector N, Amalfitano A, et al. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. International Journal of Cancer. 126: 2893-903. PMID 19856307 DOI: 10.1002/Ijc.24995 |
0.49 |
|
| 2010 |
Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA. Abstract 5338: Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody Cancer Research. 70: 5338-5338. DOI: 10.1158/1538-7445.Am10-5338 |
0.46 |
|
| 2010 |
Thomas Z, Sexton JZ, Devi GR, Williams KP. Abstract 5179: Inflammatory breast cancer cell motility: Understanding the role of E-cadherin and gli1 in IBC migration and the development of a novel high content assay to assess cell migration Cancer Research. 70: 5179-5179. DOI: 10.1158/1538-7445.Am10-5179 |
0.506 |
|
| 2010 |
Thomas ZI, Sexton JZ, Gibson W, Aird KM, Aldrich A, Devi GR, Williams KP. Abstract B67: Establishment of a high-content assay to assess the affects of gene silencing on inflammatory breast cancer cell motility Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-B67 |
0.732 |
|
| 2009 |
Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, Lyerly HK, Morse MA. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. British Journal of Cancer. 102: 124-33. PMID 19953093 DOI: 10.1038/Sj.Bjc.6605364 |
0.416 |
|
| 2009 |
Iversen PL, Aird KM, Wu R, Morse MM, Devi GR. Cellular uptake of neutral phosphorodiamidate morpholino oligomers. Current Pharmaceutical Biotechnology. 10: 579-88. PMID 19619124 DOI: 10.2174/138920109789069279 |
0.674 |
|
| 2009 |
Ding X, Mohd AB, Huang Z, Baba T, Bernardini MQ, Lyerly HK, Berchuck A, Murphy SK, Buermeyer AB, Devi GR. MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition. British Journal of Cancer. 101: 269-77. PMID 19603033 DOI: 10.1038/Sj.Bjc.6605180 |
0.447 |
|
| 2009 |
Devi GR. Delivery of phosphorodiamidate morpholino antisense oligomers in cancer cells. Methods in Molecular Biology (Clifton, N.J.). 542: 351-61. PMID 19565912 DOI: 10.1007/978-1-59745-561-9_19 |
0.388 |
|
| 2009 |
Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prevention Research (Philadelphia, Pa.). 2: 557-65. PMID 19470786 DOI: 10.1158/1940-6207.Capr-08-0188 |
0.316 |
|
| 2009 |
Freedland SJ, Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV. A NO CARBOHYDRATE DIET SIGNIFICANTLY PROLONGS SURVIVAL IN A PROSTATE CANCER XENOGRAFT MODEL VIA IGF-1 AND GLOBAL GENE EXPRESSION CHANGES Journal of Urology. 181: 47-47. DOI: 10.1016/S0022-5347(09)60144-0 |
0.32 |
|
| 2009 |
Hsu DS, Morse M, Clay T, Devi G, Lyerly HK. CHAPTER 68 – Immune Cells and the Tumor Microenvironment Genomic and Personalized Medicinevolumes I & Ii. 818-829. DOI: 10.1016/B978-0-12-369420-1.00068-8 |
0.334 |
|
| 2008 |
Aird KM, Ding X, Baras A, Wei J, Morse MA, Clay T, Lyerly HK, Devi GR. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression Molecular Cancer Therapeutics. 7: 38-47. PMID 18202008 DOI: 10.1158/1535-7163.Mct-07-0370 |
0.741 |
|
| 2008 |
Sekhon HS, London CA, Sekhon M, Iversen PL, Devi GR. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer (Amsterdam, Netherlands). 60: 347-54. PMID 18096271 DOI: 10.1016/J.Lungcan.2007.10.028 |
0.351 |
|
| 2007 |
Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. Journal of Translational Medicine. 5: 42. PMID 17822557 DOI: 10.1186/1479-5876-5-42 |
0.44 |
|
| 2005 |
Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3930-8. PMID 15897595 DOI: 10.1158/1078-0432.Ccr-04-2091 |
0.412 |
|
| 2004 |
Ko YJ, Devi GR, London CA, Kayas A, Reddy MT, Iversen PL, Bubley GJ, Balk SP. Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. The Journal of Urology. 172: 1140-4. PMID 15311058 DOI: 10.1097/01.Ju.0000134698.87862.E6 |
0.304 |
|
| 2004 |
Amantana A, London CA, Iversen PL, Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Molecular Cancer Therapeutics. 3: 699-707. PMID 15210856 |
0.366 |
|
| 2004 |
Devi GR. XIAP as target for therapeutic apoptosis in prostate cancer. Drug News & Perspectives. 17: 127-34. PMID 15098067 DOI: 10.1358/Dnp.2004.17.2.829046 |
0.441 |
|
| 2004 |
Devi G. Preface [HotTopic: Genomics-Based Anti-Cancer Drug Discovery (Guest Editor: Gayathri R. Devi)] Current Pharmaceutical Biotechnology. 5: i-i. DOI: 10.2174/1389201043376661 |
0.316 |
|
| 2003 |
London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Therapy. 10: 823-32. PMID 14605668 DOI: 10.1038/Sj.Cgt.7700642 |
0.34 |
|
| 2003 |
Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anti-Cancer Drugs. 14: 39-47. PMID 12544257 DOI: 10.1097/00001813-200301000-00006 |
0.39 |
|
| 2002 |
Devi GR, Oldenkamp JR, London CA, Iversen PL. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. The Prostate. 53: 200-10. PMID 12386920 DOI: 10.1002/Pros.10151 |
0.392 |
|
| 2002 |
Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. The Prostate. 51: 141-52. PMID 11948969 DOI: 10.1002/Pros.10068 |
0.392 |
|
| 2000 |
Lo Pez-Bermejo A, Buckway CK, Devi GR, Hwa V, Plymate SR, Oh Y, Rosenfeld RG. Characterization of Insulin-Like Growth Factor-Binding Protein-Related Proteins (IGFBP-rPs) 1, 2, and 3 in Human Prostate Epithelial Cells: Potential Roles for IGFBP-rP1 and 2 in Senescence of the Prostatic Epithelium. Endocrinology. 141: 4072-4080. PMID 28200881 DOI: 10.1210/Endo.141.11.7783 |
0.344 |
|
| Show low-probability matches. |